Geneva, May 20 -- International Clinical Trials Registry received information related to the study (ISRCTN11752949) titled 'NEOVACC: A personalised DNA vaccine for patients with advanced lung cancer' on May 8.
Study Type: Interventional
Study Design:
Single arm non-randomized study (Safety, Efficacy)
Primary Sponsor: University of Liverpool
Condition:
Non-small cell lung cancer (NSCLC) with PDL1 expression =50% which does not achieve tumour clearance with anti-PD1 treatment
Cancer
Intervention:
The NEOVACC doggybone personalised cancer vaccines (dbPCV) will be administered by PharmaJet Stratis Needle-free injection system. Participants will receive a 2mg/ml dose of dbPCV in 2 divided doses of 0.5ml every 3 weeks for the first ...